Thar Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company that reinvents known, safe, on-the-market drugs by improving clinical performance, economic benefits and patient convenience. The company focuses on transforming intravenous (IV) drugs into oral drugs for existing and new indications. Thar’s lead product T121 is a composition-of-matter patented, oral version of Novartis’ IV-only Zometa or zoledronic acid.
Thar is developing T121 in a Phase 3 program for the treatment of complex regional pain syndrome (CRPS) and has a very clear path from the regulatory agencies for its development. CRPS is an orphan disease with no approved therapies by FDA or EMA. CRPS that typically effects the extremities, and is characterized by significant pain, edema, limited range of motion, vasomotor instability, and patchy bone demineralization.